| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/11/2006 | CA2585555A1 Substituted phenylalkanoic acids |
| 05/11/2006 | CA2585550A1 Substituted carboxylic acids |
| 05/11/2006 | CA2585544A1 Pyridine imidazoles and aza-indoles as progesterone receptor modulators |
| 05/11/2006 | CA2585536A1 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| 05/11/2006 | CA2585535A1 Novel bradykinin b1 antagonists, method for producing the same and the use thereof as drugs |
| 05/11/2006 | CA2585471A1 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| 05/11/2006 | CA2585449A1 Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists |
| 05/11/2006 | CA2585423A1 Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
| 05/11/2006 | CA2585383A1 Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents |
| 05/11/2006 | CA2585373A1 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents |
| 05/11/2006 | CA2585337A1 Trisubstituted thiophenes as progesterone receptor modulators |
| 05/11/2006 | CA2585334A1 Indole derivatives useful as progesterone receptor modulators |
| 05/11/2006 | CA2585210A1 Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| 05/11/2006 | CA2585114A1 Antiviral composition |
| 05/11/2006 | CA2585095A1 Oral solid dosage forms containing a low dose of estradiol |
| 05/11/2006 | CA2585091A1 Novobiocin analogues as anticancer agents |
| 05/11/2006 | CA2585079A1 Therapeutic furopyrimidines and thienopyrimidines |
| 05/11/2006 | CA2584808A1 Substituted pyridines with activity on syk kinase |
| 05/11/2006 | CA2584684A1 Reverse micelle composition for delivery of metal cations comprising a diglyceride and a phytosterol and method of preparation |
| 05/11/2006 | CA2584681A1 Pearmease and suicide genes for antitumoral or antiviral treatment |
| 05/11/2006 | CA2584676A1 Polymorphs of sarsapogenin |
| 05/11/2006 | CA2584583A1 Lyophilized liposome formulations and method |
| 05/11/2006 | CA2584419A1 New modified release tablet formulations for proton pump inhibitors |
| 05/11/2006 | CA2584417A1 New modified release pellet formulations for proton pump inhibitors |
| 05/11/2006 | CA2584338A1 Gabapentin prodrug sustained release oral dosage forms |
| 05/11/2006 | CA2584266A1 Methods and compositions for treating chronic lymphocytic leukemia |
| 05/11/2006 | CA2584012A1 Process for treating a biological organism |
| 05/11/2006 | CA2583812A1 Compounds and compositions as hedgehog pathway modulators |
| 05/11/2006 | CA2583694A1 Amorphous and polymorphic forms of telmisartan sodium |
| 05/11/2006 | CA2583570A1 Combination comprising zd6474 and an antiandrogen |
| 05/11/2006 | CA2583517A1 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption |
| 05/11/2006 | CA2583237A1 Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists |
| 05/11/2006 | CA2582436A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists |
| 05/11/2006 | CA2582092A1 Tadalafil crystal forms and processes for preparing them |
| 05/11/2006 | CA2578854A1 Spontaneously dispersible pharmaceutical compositions |
| 05/11/2006 | CA2575764A1 Diaryl ureas as cb1 antagonists |
| 05/11/2006 | CA2566535A1 Ige-retargeting, function-altering molecules (erfam) for treatment of allergic diseases |
| 05/11/2006 | CA2560559A1 Aqueous intraocular penetration-promoting eye drop |
| 05/10/2006 | EP1655990A1 Wireless microphone communication system |
| 05/10/2006 | EP1655382A2 Colon specific gene and protein |
| 05/10/2006 | EP1655372A2 Production of polyketides and other natural products |
| 05/10/2006 | EP1655369A1 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| 05/10/2006 | EP1655367A1 Modulators of tissue regeneration |
| 05/10/2006 | EP1655361A1 Contaminant reduced marine oil |
| 05/10/2006 | EP1655302A2 Antiparasitic artemisinin derivatives (endoperoxides) |
| 05/10/2006 | EP1655301A1 Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| 05/10/2006 | EP1655300A1 Non-nucleoside reverse transcriptase inhibitors |
| 05/10/2006 | EP1655299A1 Benzothiadiazine derivatives, process of preparation thereof and pharmaceutical compositions containing them |
| 05/10/2006 | EP1655298A1 Novel polymorph forms of candesartan cilexetil |
| 05/10/2006 | EP1655296A1 Thrombin inhibitors |
| 05/10/2006 | EP1655295A1 Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| 05/10/2006 | EP1655292A1 Preventive or therapeutic composition for viral infectious disease |
| 05/10/2006 | EP1655291A1 Compounds having thrombopoietin receptor agonism |
| 05/10/2006 | EP1655290A1 Compositions comprising a benzoisothiazolone derivative and their use in the cosmetic field |
| 05/10/2006 | EP1655289A1 Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives |
| 05/10/2006 | EP1655288A1 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents |
| 05/10/2006 | EP1655287A1 Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change |
| 05/10/2006 | EP1655286A1 Process for producing low-melting crystal of free disopyramide base |
| 05/10/2006 | EP1655284A1 2-Phenylsulfopyrroles |
| 05/10/2006 | EP1655283A1 11beta-HSD1 Inhibitors |
| 05/10/2006 | EP1655281A1 Salts of N-acyl-L-aspartate-beta-mono-ester and/or of N-acyl-L-glutamate-gamma-monoester, the process for preparing them and their use in therapeutic or cosmetic compositions |
| 05/10/2006 | EP1655280A1 Dicarboxylic acid derivates with pharmaceutical properties |
| 05/10/2006 | EP1655055A1 Use of dapsone as a neuroprotector in cerebral infarction |
| 05/10/2006 | EP1655039A2 Immunoliposomes that optimize internalization into target cells |
| 05/10/2006 | EP1655037A1 Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis |
| 05/10/2006 | EP1655034A1 Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases. |
| 05/10/2006 | EP1655033A1 Nucleosides with anti-hepatitis B virus activity |
| 05/10/2006 | EP1655032A1 Compounds for the treatment of autoimmune and demyelinating diseases |
| 05/10/2006 | EP1655031A1 Use of dienogest in fixed extended cycle hormonal contraceptives |
| 05/10/2006 | EP1655030A1 Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same |
| 05/10/2006 | EP1655029A1 Medicinal compositions |
| 05/10/2006 | EP1655028A2 Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems |
| 05/10/2006 | EP1655027A1 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension and migraine |
| 05/10/2006 | EP1655026A1 Solid pharmaceutical formulations comprising diacereine and meloxicam |
| 05/10/2006 | EP1655023A1 Botulinum toxin implat |
| 05/10/2006 | EP1655015A1 Hair regenerator |
| 05/10/2006 | EP1654380A2 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
| 05/10/2006 | EP1654375A1 Biologically active oils |
| 05/10/2006 | EP1654288A1 Polysaccharides derivatives with high antithrombotic activity in plasma |
| 05/10/2006 | EP1654285A2 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 05/10/2006 | EP1654271A1 Steroid modified chacotrioses and solatrioses |
| 05/10/2006 | EP1654268A2 Lincomycin derivatives possessing antibacterial activity |
| 05/10/2006 | EP1654263A1 Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 05/10/2006 | EP1654261A1 Hepatitis c inhibitor compounds |
| 05/10/2006 | EP1654260A2 6-menbered heteroaryl compounds for the treatment of neurodegenerative disorders |
| 05/10/2006 | EP1654258A1 Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| 05/10/2006 | EP1654255A1 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| 05/10/2006 | EP1654247A1 Alkynyl aryl carboxamides |
| 05/10/2006 | EP1654241A1 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
| 05/10/2006 | EP1654232A1 Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| 05/10/2006 | EP1654231A2 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 05/10/2006 | EP1654229A1 Piperidine derivatives as ccr5 receptor modulators |
| 05/10/2006 | EP1654225A2 Melanin concentrating hormone receptor antagonists |
| 05/10/2006 | EP1654224A1 Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same |
| 05/10/2006 | EP1654221A2 Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| 05/10/2006 | EP1654220A1 Compounds for modulating cell proliferation |
| 05/10/2006 | EP1654217A1 2- adamantyl derivatives as p2x7 receptor antagonists. |
| 05/10/2006 | EP1654036A1 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| 05/10/2006 | EP1654002A2 Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
| 05/10/2006 | EP1654001A2 Medicaments for inhalation comprising steroids and a betamimetic |